Viemed Healthcare Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
23.1%projected annual EPS growth
Analyst Coverage
1analyst covering
FY Revenue (est.)
$317.3Mnext fiscal year
FY EPS (est.)
$0.46next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Sleep Therapy (PAP) Patient Count Quarterly35.9KTarget: Continued double-digit year-over-year growth
Net Capital Expenditures as % of Net Revenue Annually880.0%Target: 9.0% - 10.5%
Adjusted EBITDA Margin Quarterly1,900.0%Target: 21% - 22%
Watch Items
- Ventilation Segment Regulatory ComplianceTrigger: Further tightening of National Coverage Determination (NCD) compliance criteria by MedicareAction: Enhance clinical documentation workflows and shift sales focus toward less capital-intensive product lines like sleep and maternal health.
- Share Repurchase Program ExecutionTrigger: Repurchase of up to 5% of outstanding common sharesAction: Monitor cash generation and credit facility availability to execute opportunistic buybacks under the authorized program.
Research as of 20 Jun 2026